Travere Therapeutics (TVTX) said Thursday that Swissmedic offered temporary marketing approval for Filspari to treat adults with primary IgA nephropathy with a urine protein excretion of at least 1 gram per day.

The Swiss regulator's approval is supported by results from a phase 3 study and follows the US Food and Drug Administration's full marketing authorization along with conditional marketing approval by the European Medicines Agency, the company said.